SecBot SecBot
PRESS-RELEASE ·Filed Jun 29, 2026

REPL

Replimune, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Monitor for advisory committee outcome in late July and PDUFA decision on August 2, 2026. A positive FDA decision would be transformative; negative outcome could pressure the stock.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.20
T+0 close · Jun 29, 2026 · via day close
Latest settled
+20.27%
T+60 · $13.47
Vs SPY
+15.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $11.20entry
  2. T+1 · 5mo ago −1.16%α −1.94% · $11.07
  3. T+5 · 4mo ago +2.41%α +1.02% · $11.47
  4. T+20 · 4mo ago −13.39%α −13.11% · $9.70
  5. T+60 · 8w ago +20.27%α +15.88% · $13.47
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Replimune reported a fiscal Q4 2026 EPS miss of -$0.77 vs -$0.72 consensus, a -6.9% surprise, with no revenue. The highlight is FDA acceptance of the RP1 BLA resubmission with a PDUFA date of August 2, 2026, and an advisory committee expected in late July, representing a pivotal near-term catalyst.

Key Financial Metrics

EPS
−$0.77
est −$0.72 · -6.9%
Revenue
$0.00
est $0.00 · 0.0%
Rating
miss

Key Facts

  • FDA accepted RP1 BLA resubmission for advanced melanoma; PDUFA date August 2, 2026
  • Advisory committee meeting expected in late July 2026
  • Fiscal Q4 2026 EPS -$0.77 vs consensus -$0.72 (miss of $0.05)
  • Cash and equivalents $268.9M as of March 31, 2026; cash runway into Q1 2027
  • Net loss for Q4 $73.7M, full year $313.9M

Financial Impact

BLA approval could unlock significant revenue potential; no current product revenue. Cash burn rate suggests need for future financing if approval delayed.

cashnet loss

Risk Factors

  • FDA non-approval or complete response letter for RP1
  • Cash burn may require dilutive financing before profitability

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
8% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3318910

Track record

32 reports on REPL

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
  2. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
  5. Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  6. Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
  7. Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
  8. Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
  10. Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
Showing 10 of 32

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026